REBOOT Trial Challenges Longstanding Use of Beta Blockers After Heart Attacks

For decades, beta blockers have been a staple in post-heart attack care, but a landmark 2025 study published in *The New England Journal of Medicine* calls this practice into question. The REBOOT Trial, led by Dr. Valentin Fuster of Mount Sinai Fuster Heart Hospital and Dr. Borja Ibáñez of Spain’s Centro Nacional de Investigaciones Cardiovasculares (CNIC), found that beta blockers may not provide significant benefits for patients with preserved heart function after an uncomplicated heart attack.

The REBOOT Trial: A Major Shift in Cardiac Care

The REBOOT Trial enrolled 8,505 patients from 109 hospitals in Spain and Italy, randomly assigning them to receive beta blockers or avoid them after discharge. Participants continued to receive standard post-heart attack care, and researchers followed them for a median of nearly four years. The results revealed that beta blockers did not reduce the risk of death, repeat heart attacks, or hospitalization for heart failure in patients with normal heart function.

“This trial will reshape all international clinical guidelines,” said Dr. Fuster, highlighting the study’s potential to redefine treatment protocols. The findings align with other recent trials, such as the 2024 REDUCE-AMI study, which similarly found no significant benefits of beta blockers for patients with preserved heart function.

Sex-Specific Risks in Women

A substudy published in the *European Heart Journal* uncovered a concerning trend: women who received beta blockers had a higher risk of death, heart attack, or heart failure compared to those who did not. Among women with normal left ventricular ejection fractions (50% or higher), beta blockers were linked to a 2.7% increased absolute risk of mortality over 3.7 years. This risk was not observed in men.

Dr. Ibáñez emphasized the need for personalized treatment decisions, stating, “One-size-fits-all prescribing may no longer be appropriate for patients with preserved heart function.”

Evolution of Heart Attack Treatment

Beta blockers were once critical in reducing mortality after heart attacks, particularly in an era when coronary arteries were not reopened as quickly as they are today. Modern interventions, such as rapid artery reopening and advanced therapies like statins and antiplatelet drugs, have significantly lowered complication risks. The necessity of beta blockers in patients with minimal heart damage is now under scrutiny.

“The trial was designed to optimize heart attack care based on solid scientific evidence,” said Dr. Ibáñez. “These results will help streamline treatment, reduce side effects, and improve quality of life for thousands of patients.”

Broader Implications for Clinical Practice

The REBOOT findings suggest a shift toward more selective use of beta blockers